- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00686322
Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)
Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Lung cancer is a major cause of cancer death in Taiwan and throughout the world in both developed and developing countries. More than 75% of NSCLC patients are inoperable because of either distantly metastatic disease or disease confined to one hemithorax with one or more criteria of unresectability at the time of presentation. The prognosis of such inoperable metastatic patients is poor.
The benefit of adding chemotherapy to radiation therapy for stage III disease of NSCLC is well-established. The largest of the prospective trials was sponsored by the Radiation Therapy Oncology Group (RTOG), ECOG, and the Southwest Oncology Group (SWOG), and allocated 490 patients to receive 2 months of cisplatin + vinblastine chemotherapy followed by 60 Gy of radiation at 2 Gy per fraction; or one of two radiation-alone arms. Overall survival was statistically superior for the patients receiving chemotherapy and radiation versus the other two arms of the study (13.2 months vs 12 months, vs 11.4 months, respectively; p=0.04).
Administration of chemotherapy concurrently with radiation therapy theoretically improves local control by sensitizing the tumor to radiation, while simultaneously treating systemic disease, albeit at the expense of greater local toxicity. Two large phase III studies suggest improvement in both local control and survival with concurrent chemoradiotherapy as compared with sequential chemotherapy followed by radiation for patients with stage III NSCLC. Although rates of nonhematologic toxicity were higher on the concurrent arms, median survival time trended toward superiority in the concomitant chemotherapy plus daily radiation arm compared with the sequential arm.
One source of debate is whether the addition of induction or consolidation chemotherapy adds anything to concomitant chemoradiotherapy, with numerous intergroup trials underway. CALGB has completed a randomized phase II study of two cycles of induction chemotherapy followed by two additional cycles of the same drugs with concomitant radiotherapy. The three treatment arms included four cycles of cisplatin (80 mg/m2) combined with either gemcitabine, paclitaxel, or vinorelbine. Radiotherapy was completed during the last two cycles to a total of 66 Gy. Response rates were similar, and median survival for all patients was 17 months with no clearly superior arm evident in this randomized phase II trial.
We proposed this clinical trial to evaluate the efficacy and toxicity profile of combination chemotherapy with paclitaxel and cisplatin in previously untreated, stage IIIa/IIIb NSCLC patients who received 1 cycle of induction chemotherapy, followed by concurrent chemoradiotherapy, with 2 cycles of consolidation chemotherapy.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Taipei City, Taiwan
- Taipei VGH
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologic or cytological diagnosis of inoperable locally advanced (stage III) NSCLC.
- No prior chemotherapy, immunotherapy, or radiotherapy.
- Performance status of 0 to 2 on the Zubrod scale.
- Clinically measurable disease, defined as bidimensionally measurable lesions with clearly defined margins on x-ray, scan, or physical examination. Lesions serving as measurable disease must be at least 1 cm by 1 cm, as defined by computerized tomography (CT) scan, magnetic resonance imaging (MRI), or chest x-ray.
- Estimated life expectancy of at least 12 weeks.
- Patient compliance and geographic proximity that allow adequate follow-up.
- Adequate bone marrow reserve: white blood cell (WBC) count *4,000/mm3, platelets >100,000/mm3, and hemoglobin *10 g/dL.
- Informed consent from patient.
- Males or females 18 years of age or older.
- If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine contraceptive device [IUD], birth control pills, or barrier device) during and for three months after trial.
Exclusion Criteria:
- Active infection (at the discretion of the investigator).
- Inadequate liver function (total bilirubin >1.5 times above normal range); alanine transaminase (ALT) and aspartate transaminase (AST) greater than 3 times normal (ALT and AST may be elevated to 5 times normal in patients with known metastatic disease in the liver).
- Inadequate renal function (creatinine >2.0 mg/dL).
- Pregnancy or not using appropriate birth control during the study.
- Breast feeding.
- Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)
- Use of any investigational agent in the month before enrollment into the study.
- Patients with leukemia and/or a secondary primary carcinoma except for patients who have had curative therapy to basal cell carcinoma.
- Concomitant myelosuppressive radiotherapy, chemotherapy, hormonal therapy, or immunotherapy will not be allowed except as previously noted for radiation.
- Active cardiac disease requiring therapy for failure, angina, and/or arrhythmias; infarctions within the preceding six months (exception: any patient whose cardiac failure is compensated on medications).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: 1
Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
|
Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
To determine the efficacy of this treatment modality in patients with inoperable stage III NSCLC
Lasso di tempo: one year
|
one year
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
To determine the toxicity profiles of this treatment modality in patients with inoperable stage III NSCLC
Lasso di tempo: one year
|
one year
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Yuh-Min Chen, MD, PhD., Chest Department, Taipei VGH
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie polmonari
- Carcinoma, polmone non a piccole cellule
- Meccanismi molecolari dell'azione farmacologica
- Agenti antineoplastici
- Modulatori della tubulina
- Agenti antimitotici
- Modulatori della mitosi
- Agenti antineoplastici, fitogenici
- Paclitaxel
- Cisplatino
- Paclitaxel legato all'albumina
Altri numeri di identificazione dello studio
- 97-02-12
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Carcinoma polmonare non a piccole cellule
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group BCompletatoCarcinoma a cellule renali a cellule chiare | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti, Canada, Porto Rico
-
National Cancer Institute (NCI)TerminatoCarcinoma a cellule renali a cellule chiare | Carcinoma a cellule renali metastatico | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio IV AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti
Prove cliniche su Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
-
Huazhong University of Science and TechnologyAttivo, non reclutanteTumore gastrico | Cancro gastroesofageoCina
-
Washington University School of MedicineReclutamentoCancro esofageo | Cancro dell'esofago | Cancro all'esofagoStati Uniti
-
City of Hope Medical CenterNational Cancer Institute (NCI)ReclutamentoColangiocarcinoma intraepatico | Carcinoma della cistifellea | Colangiocarcinoma intraepatico stadio IV AJCC v8 | Neoplasia maligna metastatica nel peritoneo | Adenocarcinoma del dotto biliare distale | Cancro del dotto biliare distale in stadio IV AJCC v8 | Cancro del dotto biliare intraepatico... e altre condizioniStati Uniti
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Attivo, non reclutanteColangiocarcinoma intraepatico stadio III AJCC v8 | Colangiocarcinoma intraepatico stadio IIIA AJCC v8 | Colangiocarcinoma intraepatico stadio IIIB AJCC v8 | Cancro alla cistifellea in stadio III AJCC v8 | Cancro alla cistifellea in stadio IIIA AJCC v8 | Cancro alla cistifellea in stadio IIIB... e altre condizioniStati Uniti
-
HonorHealth Research InstituteCantex PharmaceuticalsTerminatoCancro pancreatico metastaticoStati Uniti
-
University of Southern CaliforniaNational Cancer Institute (NCI); Vasgene Therapeutics, IncTerminatoCancro polmonare non a piccole cellule in stadio IIIA | Cancro polmonare non a piccole cellule in stadio IIIB | Adenocarcinoma pancreatico | Carcinoma a cellule squamose della testa e del collo | Carcinoma polmonare non a piccole cellule ricorrente | Carcinoma polmonare non a piccole cellule... e altre condizioniStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoCarcinoma del dotto biliare extraepatico non resecabile | Carcinoma della cistifellea non resecabile | Cancro alla cistifellea in stadio IIIA AJCC v7 | Cancro alla cistifellea in stadio IIIB AJCC v7 | Cancro alla cistifellea in stadio IVA AJCC v7 | Cancro alla cistifellea in stadio IVB AJCC v7 | Colangiocarcinoma intraepatico stadio III AJCC v7 e altre condizioniStati Uniti
-
Roswell Park Cancer InstituteNovartisCompletatoNeoplasia solida maligna avanzata | Adenocarcinoma pancreatico metastatico | Cancro al pancreas in stadio III | Cancro al pancreas in stadio IV | ALK PositivoStati Uniti
-
Emory UniversityNational Cancer Institute (NCI)RitiratoColangiocarcinoma intraepatico stadio II AJCC v8 | Colangiocarcinoma intraepatico stadio III AJCC v8 | Colangiocarcinoma intraepatico resecabile | Colangiocarcinoma intraepatico stadio 0 AJCC v8 | Colangiocarcinoma intraepatico stadio I AJCC v8Stati Uniti
-
Mayo ClinicNational Cancer Institute (NCI)ReclutamentoCarcinoma pancreatico metastatico | Cancro al pancreas in stadio IV AJCC v8 | Neoplasia maligna metastatica nel peritoneoStati Uniti